IGF-1 (Insulin-like Growth Factor 1): IGF1R/IR Crosstalk, IRS-1/2 Scaffold Biology, and IGFBP Regulation in Research

# IGF-1 (Insulin-like Growth Factor 1): IGF1R/IR Crosstalk, IRS-1/2 Scaffold Biology, and IGFBP Regulation in Research

Category: Peptide Guides | Read Time: 14 min | Tags: IGF-1, IGF1R, IRS-1, IRS-2, IGFBP, insulin receptor, PI3K, Akt, mTORC1, FOXO, cancer resistance, IGF-1R inhibitor

---

For Research Use Only. Not for human or animal therapeutic use.

---

Introduction

Insulin-like growth factor 1 (IGF-1) is a 70-amino-acid, 7.6-kDa single-chain peptide that occupies a central node in growth, metabolism, and survival signaling. Structurally and functionally homologous to insulin (~48% sequence identity in the receptor-binding domains), IGF-1 acts through the IGF-1 receptor (IGF1R) — a tetrameric disulfide-linked receptor tyrosine kinase that shares remarkable structural homology with the insulin receptor (IR) and can form functional hybrid receptors with it. Unlike most cytokines and growth factors, nearly 99% of circulating IGF-1 is bound to one of six insulin-like growth factor binding proteins (IGFBPs 1–6), making the regulation of free bioavailable IGF-1 through IGFBP synthesis, proteolysis, and post-translational modification a major control point for IGF-1 biology.

The IGF-1 axis is clinically consequential far beyond its classical roles in somatic growth and metabolism: it provides a survival and proliferative bypass circuit that renders tumor cells resistant to anti-EGFR, anti-HER2, and anti-estrogen therapies through shared downstream signaling (IRS-1→PI3K/Akt→mTORC1) and bidirectional receptor crosstalk. This review covers IGF-1 gene regulation, IGF1R/IR structural biology, IRS-1/2 scaffold signaling, the IGFBP system, crosstalk with EGFR/ErbB2 and other RTKs, and the research tools available for selective axis manipulation.

---

IGF-1 Gene Regulation and Isoform Structure

The human IGF1 gene maps to chromosome 12q23.2 and spans >84 kb, organized into 6 exons with alternative promoters (P1, P2) and alternative splicing in exon 5 that generates three N-terminal leader sequences and three C-terminal E-peptide extensions (IGF-1Ea, IGF-1Eb, IGF-1Ec — the latter historically designated mechano-growth factor, MGF, in muscle biology).

Post-Translational Processing

All IGF-1 precursors are processed to the mature 70-amino-acid peptide by removal of the signal peptide and, in most tissues, the E-peptide extension. The mature IGF-1 peptide retains the four-domain architecture (B-C-A-D) shared with insulin, with the principal difference being that the C-peptide in IGF-1 is a short loop (12 residues) that remains in the mature protein rather than being excised as in insulin processing.

Disulfide Bond Architecture

IGF-1 contains three intramolecular disulfide bonds:

• •Cys6–Cys48 (B-A chain link)
• •Cys18–Cys61 (B-D domain)
• •Cys47–Cys52 (A-chain internal)

These bonds stabilize the insulin-like fold and are absolutely required for IGF1R binding. Recombinant IGF-1 expressed in E. coli requires oxidative refolding to form correct disulfide pairings; lot-to-lot QC by bioactivity assay is essential since incorrect disulfide isomers bind IGF1R with >100-fold reduced affinity.

GH/IGF-1 Axis

The principal physiological regulator of hepatic IGF-1 production is growth hormone (GH), which activates hepatocyte JAK2/STAT5B → IGF1 transcription. Approximately 75% of circulating IGF-1 is liver-derived (endocrine IGF-1); the remainder is produced locally in muscle, bone, brain, and other tissues (autocrine/paracrine IGF-1) regulated by tissue-specific factors including estrogen, thyroid hormone, and nutritional status (mTORC1 in liver suppresses IGF-1 production under nutrient excess — a negative feedback loop).

---

IGF1R Structure: The Tetrameric Prealigned Dimer

IGF1R is constitutively organized as a disulfide-linked (αβ)₂ tetramer at the cell surface — in contrast to EGFR, which exists as monomers that dimerize upon ligand binding. The tetramer consists of:

• •Two α-subunits (extracellular; 706 aa each): contain the ligand-binding domains (L1, Cys-rich, L2, fibronectin type III domains); encoded by the N-terminal half of the IGF1R precursor
• •Two β-subunits (transmembrane + cytoplasmic; 627 aa each): contain a single transmembrane helix, juxtamembrane domain, tyrosine kinase domain, and C-terminal tail

The α and β subunits are covalently linked by Cys647α–Cys872β interchain disulfide bonds; the two αβ protomers are linked by α–α disulfide bonds at Cys683α–Cys683α (symmetric). This pre-dimerized architecture means IGF1R does not require ligand-induced dimerization for activation — instead, IGF-1 induces a conformational change within the pre-existing tetramer that repositions the two β-subunit kinase domains for trans-autophosphorylation.

Activation Loop Phosphorylation

IGF-1 binding to the α-subunit L1/L2 domains induces conformational changes transmitted through the transmembrane helices that allow trans-autophosphorylation of Tyr1135, Tyr1136 (primary activation loop tyrosines; analogous to IR Tyr1158/Tyr1162/Tyr1163) and subsequent phosphorylation of Tyr950 (juxtamembrane domain — the primary IRS docking site), Tyr1131, Tyr1161, Tyr1250, Tyr1251 (C-tail).

---

IR/IGF1R Hybrid Receptors

Because IR and IGF1R are structurally homologous tetramers that are often co-expressed, they can exchange half-receptors (one αβ protomer from IR + one αβ protomer from IGF1R) to form hybrid receptors (HR-A or HR-B) depending on which IR isoform (IR-A or IR-B) is incorporated. HR-A incorporates IR-A (which lacks the 12-amino-acid exon 11 domain); HR-B incorporates IR-B.

Ligand selectivity of hybrid receptors: Hybrid receptors bind IGF-1 and IGF-2 with high affinity (similar to IGF1R homodimers) but bind insulin with low affinity (similar to IGF1R). The practical implication: in insulin-resistant states or cancer cells that upregulate IR expression, hybrid receptor formation proportionally reduces insulin-responsive signaling capacity while maintaining full IGF-1 responsiveness — potentially contributing to insulin resistance and IGF-1-driven cancer cell survival.

IGF-2 and IR-A: IGF-2 binds not only IGF1R and hybrid receptors but also IR-A (the fetal isoform, re-expressed in many cancers) with high affinity (~10 nM), while binding IR-B with much lower affinity (~300 nM). This makes IR-A a functional IGF-2 receptor in tumors — relevant because IGF-2 is the predominant fetal IGF and is frequently imprinted/overexpressed in Wilms tumor, colorectal cancer, and hepatocellular carcinoma.

---

IRS-1 and IRS-2: The Scaffold Architecture

The insulin receptor substrate (IRS) family proteins — primarily IRS-1 (~131 kDa) and IRS-2 (~137 kDa) — are cytoplasmic scaffolds that serve as the primary signal-transducing intermediaries for both IGF1R and IR. They are not enzymes but rather multi-site phosphorylation platforms.

Domain Architecture

• •N-terminal PH domain: binds PIP3 and PIP2 at the plasma membrane; co-localizes IRS with receptor and PI3K products
• •PTB domain (phosphotyrosine binding): binds pTyr950 of IGF1R (and analogous IR pTyr972) via the NPXY motif — this is the primary docking interaction
• •Central/C-terminal tail: ~20 tyrosine residues that, when phosphorylated by IGF1R/IR, create docking sites for SH2-domain-containing effectors; ~70 serine/threonine residues that are phosphorylated by inhibitory kinases (IRS-1 Ser307, Ser612, Ser632, Ser636, Ser1101) to terminate or attenuate signaling

IRS Tyrosine Phosphorylation: Activating Outputs

Key pTyr sites and their effectors on IRS-1:

• •pTyr608/pTyr628/pTyr658/pTyr731/pTyr941: recruit p85α/β (PI3K regulatory subunit) SH2 domains → PI3K activation → PIP3 → Akt
• •pTyr895: recruits Grb2 → Sos → RAS → ERK1/2
• •pTyr1172/pTyr1222: additional PI3K p85 docking sites

The combinatorial recruitment of multiple p85 molecules to IRS-1 generates substantially more PI3K activity than equivalent EGFR-driven p85 recruitment — explaining why IGF-1/IRS-1/PI3K signaling is proportionally more dependent on PI3K than EGFR signaling for cell survival.

IRS Serine Phosphorylation: The Feedback Inhibition Code

mTORC1 and S6K1 (activated downstream of IGF-1/IRS-1/PI3K/Akt/mTORC1) phosphorylate IRS-1 at Ser307, Ser612, Ser632/636, and Ser1101, disrupting the IRS-1/IGF1R docking interaction and promoting IRS-1 proteasomal degradation. This creates a negative feedback loop (IGF-1 → mTORC1 → IRS-1 Ser phosphorylation → reduced IRS-1 signaling) that limits the duration and amplitude of IGF-1 responses. Disrupting this feedback — as occurs with rapamycin treatment (mTORC1 inhibitor) — paradoxically increases IRS-1 tyrosine phosphorylation and enhances Akt signaling in some contexts, explaining rapalogs' incomplete anti-tumor efficacy and their pro-IGF-1-signaling side effect.

IRS-1 vs. IRS-2: Differential Outputs

Despite structural similarity, IRS-1 and IRS-2 have distinct tissue distributions and downstream efficiencies:

• •IRS-1: dominant in muscle and fat; primary ERK activation scaffold; loss of IRS-1 → muscle insulin resistance; IRS-1 overexpression correlates with poor prognosis in several cancer types
• •IRS-2: dominant in liver and β-cells; more efficient at PI3K activation in hepatocytes; IRS-2-PI3K-Akt promotes hepatic lipogenesis; IRS-2 mediates IGF-1-driven breast cancer metastasis via FAK activation

---

Downstream Signaling: PI3K/Akt/mTORC1/FOXO Axis

PI3K/PIP3/PDK1/Akt

IGF-1/IRS-1/p85 → PI3Kα (p85/p110α) → PIP3 at inner plasma membrane leaflet → PDK1 (PH domain docking) → Akt Thr308 phosphorylation. Full Akt activation requires additional Ser473 phosphorylation by mTORC2 (distinct from mTORC1 — note that rapamycin primarily inhibits mTORC1, not mTORC2, and mTORC2 remains active in many rapamycin-treated cells, maintaining Akt Ser473 phosphorylation).

mTORC1: The Growth and Translation Hub

Akt → TSC2 (Thr1462) phosphorylation → TSC1/TSC2 complex inactivation → Rheb-GTP accumulates → mTORC1 activation (RAPTOR-mTOR-mLST8 complex):

• •S6K1 (Thr389): phosphorylates ribosomal S6 protein → ribosome biogenesis; eIF4B → cap-dependent translation
• •4E-BP1 (Ser65, Thr70, Thr37/46): releases eIF4E → 5' cap-dependent mRNA translation of growth-promoting mRNAs (cyclin D1, c-Myc, ornithine decarboxylase)
• •IRS-1 Ser307/Ser612 negative feedback (via S6K1): as described above

FOXO Transcription Factors

Akt phosphorylates FOXO1 (Thr24, Ser256, Ser319), FOXO3a (Thr32, Ser253, Ser315), and FOXO4, creating 14-3-3 docking sites → cytoplasmic sequestration and transcriptional inactivation. FOXO nuclear target genes include: CDKN1B (p27, anti-proliferative), BIM (pro-apoptotic), FASL (pro-apoptotic), PTEN (PI3K antagonist), SOD2 (antioxidant defense). IGF-1/Akt-driven FOXO inactivation therefore simultaneously promotes cell cycle progression (p27↓), survival (BIM↓), and oxidative stress resistance (SOD2↓).

FOXO3a nuclear localization in quiescent cells is a key reason IGF-1 deprivation triggers the rapid apoptosis of IGF-1-dependent cell lines: Akt-mediated FOXO inhibition is actively maintained, not simply absent, and withdrawal removes an active survival signal rather than simply failing to deliver a growth signal.

RAS/ERK Branch

pTyr895 on IRS-1 → Grb2/Sos → RAS → RAF → MEK → ERK1/2: drives cyclin D1 transcription and cell cycle progression. IRS-1/Grb2 is less efficient than EGFR/Grb2 at ERK activation, explaining why IGF-1 signaling is disproportionately PI3K/Akt-dependent compared to EGFR signaling at equivalent receptor activation levels.

---

The IGFBP System: Regulation of Free IGF-1 Bioavailability

Six IGFBPs (IGFBP-1 through IGFBP-6) bind IGF-1 and IGF-2 with affinities typically 2- to 50-fold higher than IGF1R, making them competitive inhibitors of IGF1R binding. However, IGFBP biology is far more nuanced than simple inhibition:

IGFBP-3: The Dominant Circulating Carrier

IGFBP-3 (~40 kDa) is the most abundant serum IGFBP, forming a ternary complex with IGF-1/IGF-2 and the acid-labile subunit (ALS; IGFALS) to create a ~150 kDa trimeric carrier complex that extends IGF-1 serum half-life from ~10 min (free) to ~16 hours. IGFBP-3 is itself transcriptionally regulated by GH/STAT5B, p53 (tumor suppressor — IGFBP-3 is a p53 target gene and its downregulation in cancer reduces the anti-proliferative function of p53), and TGF-β1.

IGFBP-3 IGF-independent actions: IGFBP-3 has nuclear localization sequences and can translocate to the nucleus where it interacts with retinoid X receptor-α (RXRα) and p53 to regulate apoptotic gene expression independently of IGF-1 binding. These IGF-independent actions complicate interpretation of IGFBP-3 overexpression experiments.

IGFBP-1: The Acute Regulation Axis

IGFBP-1 (~25 kDa) is acutely regulated by insulin (which suppresses its hepatic transcription via FOXO1) and nutritional status (fasting → IGFBP-1 ↑ → IGF-1 bioavailability ↓). IGFBP-1 also contains an RGD integrin-binding motif and can modulate cell migration independently of its IGF-1 sequestration function.

IGFBP Proteolysis: Releasing Bioactive IGF-1

IGFBPs are cleaved by a variety of proteases that release free IGF-1 at target tissues:

• •PAPP-A (pregnancy-associated plasma protein A): metalloproteinase that cleaves IGFBP-4 and IGFBP-5; expressed at sites of active IGF-1 signaling (bone, ovary, atherosclerotic plaques)
• •Kallikreins (KLK2, KLK3/PSA): cleave IGFBP-3; relevant in the prostate — PSA-cleaved IGFBP-3 releases IGF-1 in the prostate microenvironment
• •MMP-1, -2, -3, -9: cleave IGFBP-1, -2, -3 at the tumor microenvironment; cancer-associated fibroblast MMPs increase local free IGF-1 availability for tumor cells

IGFBP-2: Tumor Microenvironment Role

IGFBP-2 (~34 kDa) is overexpressed in glioblastoma, prostate cancer, and AML. Unlike most IGFBPs that inhibit IGF-1, IGFBP-2 has a heparin-binding domain that tethers it to cell surfaces and ECM, where it can serve as a local IGF-1 concentrator/presenter rather than inhibitor — enhancing rather than reducing IGF1R activation at short range. IGFBP-2 also activates integrin signaling (αvβ3) via its RGD motif, contributing to invasion independently of IGF-1.

---

IGF-1R Crosstalk with EGFR/ErbB2 and Resistance Biology

The IGF-1/IGF1R axis is mechanistically entangled with EGFR/ErbB family signaling through:

Direct Receptor Cross-Phosphorylation

IGF1R and EGFR can physically associate (co-immunoprecipitation) in lipid raft microdomains and activate each other via trans-phosphorylation. IGF1R kinase phosphorylates EGFR at Tyr845 (Src-site, activating) and Tyr1068 (Grb2 docking site), contributing to EGFR activation in the absence of EGF. This is particularly relevant in HER2-overexpressing breast cancer where IGF1R/ErbB2 heterocomplexes sustain PI3K/Akt signaling.

Shared IRS-1/PI3K Pathway Convergence

Both EGFR and IGF1R converge on IRS-1 → PI3K → Akt, creating pathway redundancy. When EGFR is inhibited by gefitinib/erlotinib, residual IGF-1/IGF1R signaling maintains IRS-1-driven PI3K/Akt activation — a documented resistance mechanism in NSCLC, head and neck squamous cell carcinoma (HNSCC), and ER+ breast cancer.

IGF1R as Anti-EGFR Resistance Mediator

Multiple studies demonstrate that:

1. Anti-EGFR antibody (cetuximab) treatment upregulates IGF1R expression and IGF-1-driven signaling

2. Combined EGFR + IGF1R inhibition more completely suppresses PI3K/Akt and synergistically reduces tumor growth in EGFR-dependent models

3. High IGF1R expression predicts poor response to EGFR-targeted therapy in colorectal and head-and-neck cancers

IGF-1/Estrogen Receptor (ER) Crosstalk

In breast cancer, IGF-1 activates ER in a ligand-independent manner: IGF1R→IRS-1→ERK1/2→ER Ser118 phosphorylation → ER transcriptional activation without estrogen. This mechanism underlies partial resistance to anti-estrogen agents in high-IGF-1 environments and motivates combining IGF1R inhibitors with aromatase inhibitors or selective estrogen receptor degraders (SERDs) in ER+ breast cancer research models.

---

Research Tools for IGF-1R/IRS-1 Axis Manipulation

IGF1R Kinase Inhibitors

OSI-906 (linsitinib; Sigma SML1196): Dual IGF1R/IR kinase inhibitor; IC50 ~35 nM (IGF1R), ~75 nM (IR); ~100× selectivity over EGFR, VEGFR, FGFR. The most widely validated IGF1R kinase research tool; working concentration 100 nM–1 µM for cellular IGF1R blockade. Important: since it co-inhibits IR, metabolic effects (glucose uptake reduction) confound pure IGF-1 signaling studies in insulin-sensitive cell types — account for with IR-selective controls.

BMS-536924 (Sigma SML1190): Dual IGF1R/IR inhibitor; IC50 ~100 nM (IGF1R), ~73 nM (IR); comparable to OSI-906 for research use; use at 250 nM–2 µM.

NVP-AEW541 (Sigma SML0925): IGF1R-selective over IR (~26-fold: IC50 ~150 nM IGF1R vs. ~2.8 µM IR); best choice when IR co-inhibition must be avoided. Use at 500 nM–3 µM for IGF1R-selective blockade.

Picropodophyllin (PPP; Sigma SML0525): Cyclolignan-class IGF1R inhibitor with unusual allosteric mechanism (non-ATP-competitive); IC50 ~50 nM (IGF1R); does not inhibit IR; minimal activity on EGFR. Particularly useful for IGF1R-selective studies. Note: PPP also inhibits Aurora kinase A at similar concentrations — this off-target must be controlled.

Anti-IGF1R Antibodies

Ganitumab (AMG 479; R&D Systems for research MAB391): Fully human anti-IGF1R IgG1; blocks IGF-1 and IGF-2 binding to IGF1R; IC50 ~1 nM in competition assays; does not bind IR. Use at 1–10 µg/mL for ligand-blocking experiments. ADCC-capable.

Figitumumab (CP-751871): IgG2 anti-IGF1R; IGF1R-selective (no IR binding); blocks both IGF-1 and IGF-2. Use at 2–20 µg/mL.

Anti-IGF1R (clone 24-57, Abcam ab39547): Research antibody for western blot/IHC/flow cytometry detection; not a blocking antibody; clone validates across human, mouse, rat samples.

Recombinant IGF-1 Protein

R&D Systems 291-G1 (human IGF-1, carrier-free): E. coli-derived mature 70-aa IGF-1; single-chain; EC50 for Akt phosphorylation ~1–10 ng/mL (cell-based, IGF1R-expressing cells). Storage: reconstitute in 10 mM acetic acid + 0.1% BSA at 100 µg/mL; aliquot; −80°C.

Long R³ IGF-1 (GroPep): Analog with N-terminal extension and Arg³→Arg substitution that reduces IGFBP binding affinity by >1000-fold vs. native IGF-1 while preserving IGF1R binding; EC50 typically 2–5 ng/mL for cell-based assays. Use when IGFBP interference in conditioned medium or serum-containing medium must be eliminated. The standard IGF-1 analog in serum-free media formulations for stem cell and feeder-free culture.

Des(1-3)IGF-1: N-terminal tripeptide deletion that reduces IGFBP binding ~2000-fold; retains IGF1R binding; research tool for isolating receptor-level from IGFBP-level regulation.

IGFBP Recombinant Proteins and Tools

• •IGFBP-3 (R&D Systems 675-B3): Human recombinant; use at 100–1000 ng/mL to sequester endogenous IGF-1 in conditioned medium without affecting receptor directly; requires pre-incubation with IGF-1 (15 min at RT) before adding to cells for effective competition
• •PAPP-A recombinant (R&D Systems 4697-ZN): To study IGFBP-4 cleavage and local IGF-1 release; use at 0.1–10 µg/mL
• •Anti-IGFBP-3 neutralizing antibody (R&D Systems AF675): Blocks IGFBP-3 in conditioned medium to study its contribution to ambient IGF-1 inhibition

mTOR/S6K Pathway Research Tools (IGF-1 Downstream)

• •Rapamycin (Sigma R8781): mTORC1 inhibitor; IC50 ~0.1 nM; use at 1–100 nM for mTORC1 blockade; does not acutely inhibit mTORC2 (hence pAkt Ser473 remains); reveals IRS-1 serine feedback de-repression at 50–100 nM
• •Torin-1 (Tocris 4247): ATP-competitive mTOR kinase inhibitor (blocks both mTORC1 and mTORC2); IC50 ~2 nM; use at 10–100 nM for complete mTOR blockade; inhibits pAkt Ser473 unlike rapamycin
• •MK-2206 (Sigma SML0870): Allosteric pan-Akt inhibitor; IC50 ~8 nM (Akt1), ~12 nM (Akt2), ~65 nM (Akt3); use at 1–10 µM; does not inhibit PDK1; most Akt-selective research tool

---

Experimental Protocols for IGF-1/IGF1R Research

Protocol 1: IGF1R Activation and IRS-1 Tyrosine Phosphorylation Cascade

1. Starve cells in serum-free medium (+ 0.1% BSA) for 4–6h; serum contains IGFBPs and IGF-1 that establish baseline signaling.

2. Stimulate with IGF-1 (1–100 ng/mL) or Long R³ IGF-1 (1–50 ng/mL) for 5, 15, 30, 60 min.

3. Lyse; IP IRS-1 (anti-IRS-1, Cell Signaling #2382, 4 µg per 500 µg protein); blot with anti-phosphotyrosine (4G10 Millipore, 1:1000) and anti-IRS-1 total.

4. Direct lysate western: pIGF1Rβ Y1135/Y1136 (Cell Signaling #3024, 1:1000), pAkt S473 (#4060, 1:2000), pERK1/2 T202/Y204 (#4370, 1:2000), pS6K1 T389 (#9234, 1:1000), pFOXO1 T24 (#9464, 1:1000).

5. OSI-906 (500 nM, 30 min pre) and NVP-AEW541 (1 µM, 30 min pre) as parallel inhibitor controls; compare to wortmannin (100 nM) to confirm PI3K-dependency of Akt response.

Protocol 2: IGFBP Competition Assay (Free vs. Bound IGF-1 Titration)

1. Prepare IGF-1 + IGFBP-3 mixtures at molar ratios 1:0, 1:0.5, 1:1, 1:2, 1:5 (keep total IGF-1 constant at 50 ng/mL; vary IGFBP-3 from 0 to 250 ng/mL).

2. Pre-incubate at RT 30 min to allow complex formation before adding to serum-starved cells.

3. Stimulate cells 15 min at 37°C; assess pIGF1Rβ and pAkt by western blot.

4. Expected: progressive attenuation of IGF1R/Akt activation with increasing IGFBP-3; compare to equivalent experiment with Long R³ IGF-1 (IGFBP-resistant) — Long R³ responses should be unaffected by IGFBP-3 addition, confirming IGFBP-dependence of native IGF-1 inhibition.

Protocol 3: IGF1R/EGFR Crosstalk Bypass Assay

1. Treat EGFR-dependent cells (A549 NSCLC or A431 epidermoid) with gefitinib (500 nM) for 1h to block EGFR.

2. Add IGF-1 (50 ng/mL) ± OSI-906 (500 nM) to cells receiving gefitinib.

3. Assess at 30 min: pEGFR Y1068 (gefitinib-suppressed), pIGF1Rβ Y1135/1136 (IGF-1-stimulated), pAkt S473, pERK1/2.

4. Expected: gefitinib suppresses pEGFR but not pAkt when IGF-1 is present; OSI-906 co-treatment restores pAkt suppression, demonstrating IGF1R bypass of EGFR inhibition.

5. Cell viability (CellTiter-Glo, 72h): gefitinib alone reduces viability ~50%; gefitinib + OSI-906 synergistically reduces viability (confirm by Bliss or Loewe synergy analysis).

Protocol 4: IRS-1 Serine Phosphorylation Feedback Quantification

1. Treat IGF-1-sensitive cells with IGF-1 (50 ng/mL) ± rapamycin (10 nM, pre-treat 1h to block mTORC1-S6K1 feedback) for a time course (0, 15, 30 min, 1h, 2h, 4h).

2. IP IRS-1; blot with anti-IRS-1 Ser612 (Cell Signaling #3203) and anti-pTyr (4G10) in parallel blots.

3. Expected: without rapamycin, pIRS-1 Tyr peaks at 15–30 min then declines (feedback-driven Ser phosphorylation displaces Tyr signal); with rapamycin, pIRS-1 Tyr is maintained at higher amplitude for longer (mTORC1-S6K1 feedback blocked).

4. Also assess pAkt S473 ± rapamycin: classic rapamycin paradox — rapamycin may paradoxically increase pAkt Ser473 by de-repressing IRS-1-PI3K while not blocking mTORC2.

Protocol 5: Soft Agar Colony Formation (IGF-1-Driven Anchorage-Independent Growth)

1. Prepare base layer: 0.5% noble agar in DMEM + 10% FBS in 6-well plates; allow to solidify at RT.

2. Top layer: 2000 cells per well in 0.35% noble agar + DMEM + 5% FBS ± IGF-1 (50–200 ng/mL) ± OSI-906 (500 nM) ± ganitumab (10 µg/mL).

3. Refresh 100 µL of treatment medium every 3–4 days for 14–21 days.

4. Stain colonies with 0.005% crystal violet in PBS (overnight); image with colony counter or GelCount (Oxford Optronix); quantify colony number and average diameter.

5. Expected: IGF-1 significantly increases colony number and size in IGF1R-expressing cells; OSI-906 and ganitumab abolish IGF-1-driven colonization; validate specificity with IGF1R knockdown (siRNA) control.

---

Key Research Tools Summary

---

Conclusion

IGF-1/IGF1R signaling integrates growth, metabolism, and survival through a scaffold-centric architecture where IRS-1/2 serves as a multi-site phosphorylation platform that routes PI3K/Akt/mTORC1 and RAS/ERK signals with tissue-specific efficiency. The IGFBP system adds a dynamic extracellular regulation layer — proteolytic IGFBP cleavage at specific tissue sites (PAPP-A, kallikreins, MMPs) locally amplifies IGF-1 bioavailability in ways that serum total IGF-1 measurements systematically miss.

The IGF-1/EGFR bidirectional crosstalk, IRS-1/PI3K convergence, and IGF-2/IR-A signaling in cancer cells create a resistance bypass circuit that has frustrated single-agent anti-cancer strategies targeting EGFR, ErbB2, or estrogen receptors. Mechanistic dissection of these bypass routes requires the selective tool portfolio described here: NVP-AEW541 (IGF1R-selective kinase inhibitor), Long R³ IGF-1 (IGFBP-insensitive agonist), and ganitumab (ligand-blocking antibody) provide complementary approaches to isolate IGF1R-specific signaling from confounding IR, IGFBP, or receptor transactivation contributions.

---

References

1. LeRoith D, et al. The somatomedin hypothesis: 2001. Endocr Rev. 2001;22(1):53–74.

2. Adams TE, et al. Structure and function of the type 1 insulin-like growth factor receptor. Cell Mol Life Sci. 2000;57(7):1050–1093.

3. White MF. IRS proteins and the common path to diabetes. Am J Physiol Endocrinol Metab. 2002;283(3):E413–E422.

4. Foulstone E, et al. Insulin-like growth factor ligands, receptors, and binding proteins in cancer. J Pathol. 2005;205(2):145–153.

5. Baserga R. The IGF-I receptor in cancer research. Exp Cell Res. 1999;253(1):1–6.

6. Sachdev D, Yee D. Disrupting insulin-like growth factor signaling as a potential cancer therapy. Mol Cancer Ther. 2007;6(1):1–12.

7. Engelman JA, et al. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet. 2006;7(8):606–619.

8. Pollak M. Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer. 2008;8(12):915–928.

9. Jones JI, Clemmons DR. Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev. 1995;16(1):3–34.

10. Huang F, et al. The mechanisms of differential sensitivity to an insulin-like growth factor-1 receptor inhibitor (BMS-536924) and rationale for combining with EGFR/ErbB2 inhibitors. Cancer Res. 2009;69(1):161–170.